Novel Dosing Strategies Increase Exposures of the Potent Antituberculosis Drug Rifapentine but Are Poorly Tolerated in Healthy Volunteers

Rifapentine is a potent antituberculosis drug currently in phase III trials. Bioavailability decreases with increasing dose, yet high daily exposures are likely needed to improve efficacy and shorten the tuberculosis treatment duration. Further, the limits of tolerability are poorly defined. The pha...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Antimicrob Agents Chemother
Main Authors: Dooley, Kelly E., Savic, Radojka M., Park, Jeong-Gun, Cramer, Yoninah, Hafner, Richard, Hogg, Evelyn, Janik, Jennifer, Marzinke, Mark A., Patterson, Kristine, Benson, Constance A., Hovind, Laura, Dorman, Susan E., Haas, David W.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society for Microbiology 2015
Assuntos:
Pharmacology
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4432148/
https://ncbi.nlm.nih.gov/pubmed/25824215
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/AAC.05128-14
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados